期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 6, 期 5-6, 页码 244-256出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201100042
关键词
Glycoproteins; Glycoproteomics; Lung cancer; Nonsmall cell lung cancer (NSCLC); Protein biomarkers
资金
- Drs. Ji and Li Family Foundation
- National Institutes of Health/the National Cancer Institute/Early Detection Research Network (NIH/NCI/EDRN) [(NIH/NCI/EDRN) U01CA152812]
Lung cancer is the leading cause of cancer-related deaths in the United States. Approximately 4060% of lung cancer patients present with locally advanced or metastatic disease at the time of diagnosis. Lung cancer development and progression are a multistep process that is characterized by abnormal gene and protein expressions ultimately leading to phenotypic change. Glycoproteins have long been recognized to play fundamental roles in many physiological and pathological processes, particularly in cancer genesis and progression. In order to improve the survival rate of lung cancer patients, the discovery of early diagnostic and prognostic biomarkers is urgently needed. Herein, we reviewed the recent technological developments of glycoproteomics and published data in the field of glycoprotein biomarkers in lung cancer, and discussed their utility and limitations for the discovery of potential biomarkers in lung cancer. Although numerous papers have already acknowledged the importance of the discovery of cancer biomarkers, the systemic study of glycoproteins in lung cancer using glycoproteomic approaches is still suboptimal. Recent development in the glycoproteomics will provide new platforms for identification of potential protein biomarkers in lung cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据